Antibodies recognizing the C terminus of PP2A catalytic subunit are unsuitable for evaluating PP2A activity and holoenzyme composition

被引:25
|
作者
Frohner, Ingrid E. [1 ]
Mudrak, Ingrid [1 ]
Kronlachner, Stephanie [1 ]
Schuechner, Stefan [1 ]
Ogris, Egon [1 ]
机构
[1] Med Univ Vienna, Max Perutz Labs, Ctr Med Biochem, Vienna BioCtr, Dr Bohr Gasse 9, A-1030 Vienna, Austria
关键词
PROTEIN PHOSPHATASE 2A; LEUCINE CARBOXYL METHYLTRANSFERASE; REGULATORY SUBUNIT; CRYSTAL-STRUCTURE; METHYLATION; SPECIFICITY; BINDING; ASSOCIATION; MUTANTS; TYPE-2A;
D O I
10.1126/scisignal.aax6490
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The methyl-esterification of the C-terminal leucine of the protein phosphatase 2A (PP2A) catalytic (C) subunit is essential for the assembly of specific trimeric PP2A holoenzymes, and this region of the C subunit also contains two threonine and tyrosine phosphorylation sites. Most commercial antibodies-including the monoclonal antibody 1D6 that is part of a frequently used, commercial phosphatase assay kit-are directed toward the C terminus of the C subunit, raising questions as to their ability to recognize methylated and phosphorylated forms of the enzyme. Here, we tested several PP2A C antibodies, including monoclonal antibodies 1D6, 7A6, G-4, and 52F8 and the polyclonal antibody 2038 for their ability to specifically detect PP2A in its various modified forms, as well as to coprecipitate regulatory subunits. The tested antibodies preferentially recognized the nonmethylated form of the enzyme, and they did not coimmunoprecipitate trimeric holoenzymes containing the regulatory subunits B or B', an issue that precludes their use to monitor PP2A holoenzyme activity. Furthermore, some of the antibodies also recognized the phosphatase PP4, demonstrating a lack of specificity for PP2A. Together, these findings suggest that reinterpretation of the data generated by using these reagents is required.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] PP2A and tumor radiotherapy
    Xiao Lei
    Na Ma
    Lehui Du
    Yanjie Liang
    Pei Zhang
    Yanan Han
    Baolin Qu
    Hereditas, 157
  • [22] Therapeutic targeting of PP2A
    O'Connor, Caitlin M.
    Perl, Abbey
    Leonard, Daniel
    Sangodkar, Jaya
    Narla, Goutham
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2018, 96 : 182 - 193
  • [23] PP2A and Alzheimer Disease
    Torrent, L.
    Ferrer, I.
    CURRENT ALZHEIMER RESEARCH, 2012, 9 (02) : 248 - 256
  • [24] PP2A in B cells
    Dempsey, Laurie A.
    NATURE IMMUNOLOGY, 2018, 19 (06) : 510 - 510
  • [25] PP2A in B cells
    Laurie A. Dempsey
    Nature Immunology, 2018, 19 : 510 - 510
  • [26] Regulation of hepatic protein phosphatase 2A (PP2A): Role of catalytic subunit methylation
    Yoo, JS
    Gruppuso, PA
    FASEB JOURNAL, 2006, 20 (05): : A924 - A925
  • [27] PP2A in meiotic oocytes
    Yan, Xiumin
    Zhu, Xueliang
    CELL CYCLE, 2016, 15 (15) : 1950 - 1951
  • [28] Integrator of PP2A and transcription
    Minju Ha
    Nature Reviews Molecular Cell Biology, 2021, 22 : 72 - 73
  • [29] Integrator of PP2A and transcription
    Ha, Minju
    NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2021, 22 (02) : 72 - 73
  • [30] Dysregulation of PP2A activity by a mechanism involving suppressed PP2A a expression may result in chemoresistance in AML.
    Suck, G
    Jiffar, T
    Konopleva, M
    Andreeff, M
    Ruvolo, P
    BLOOD, 2003, 102 (11) : 214B - 214B